OncoCyte Corp (OCX): There have been price expectations and a...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	75
Posts	5498
Boards Moderated	0
Alias Born	10/19/2006

DMOST

Re: None

Thursday, 02/07/2019 7:09:48 AM

Thursday, February 07, 2019 7:09:48 AM

There have been price expectations and analytical upgrades to as much as $8 a share?

With news of any substance share price could flow past recent resistance near $7?

WE WILL SEE!

GO OCX

"PEACE"

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent OCX News

Oncocyte Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/12/2024 10:00:00 AM
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/12/2024 01:46:37 AM
Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:39:38 PM
Oncocyte to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:19:59 PM
Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:05:24 PM
Oncocyte Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 12:00:00 PM
Oncocyte to Announce Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/03/2023 12:30:00 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/12/2023 08:30:57 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/10/2023 08:48:39 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 08:05:37 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 01:00:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 08:05:23 PM
Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/17/2023 10:57:33 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:50:24 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:05:36 AM
VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients • GlobeNewswire Inc. • 07/25/2023 01:08:17 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 09:28:38 PM
Oncocyte Announces 1-For-20 Reverse Stock Split • GlobeNewswire Inc. • 07/24/2023 05:35:32 PM
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/21/2023 09:16:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/14/2023 10:03:15 AM
Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/10/2023 03:20:07 PM

More OCX News

InvestorsHub NewsWire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM

Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM

Start posting your company's news

Only $200 per official company press release!

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover